KR20160142587A - Method for cardiomyogenic differntiation of stem cells by applying electric and mechanical signals - Google Patents
Method for cardiomyogenic differntiation of stem cells by applying electric and mechanical signals Download PDFInfo
- Publication number
- KR20160142587A KR20160142587A KR1020150078511A KR20150078511A KR20160142587A KR 20160142587 A KR20160142587 A KR 20160142587A KR 1020150078511 A KR1020150078511 A KR 1020150078511A KR 20150078511 A KR20150078511 A KR 20150078511A KR 20160142587 A KR20160142587 A KR 20160142587A
- Authority
- KR
- South Korea
- Prior art keywords
- stem cells
- piezoelectric material
- support
- cells
- myocardial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 49
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 38
- 230000001625 cardiomyogenic effect Effects 0.000 title description 2
- 230000000638 stimulation Effects 0.000 claims description 59
- 210000004027 cell Anatomy 0.000 claims description 44
- 239000000463 material Substances 0.000 claims description 40
- 230000002107 myocardial effect Effects 0.000 claims description 40
- 239000010410 layer Substances 0.000 claims description 35
- 239000002073 nanorod Substances 0.000 claims description 35
- 238000005452 bending Methods 0.000 claims description 16
- 230000033001 locomotion Effects 0.000 claims description 16
- 230000001965 increasing effect Effects 0.000 claims description 9
- 239000002356 single layer Substances 0.000 claims description 6
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims description 2
- 239000003989 dielectric material Substances 0.000 claims description 2
- 210000004700 fetal blood Anatomy 0.000 claims description 2
- 210000001178 neural stem cell Anatomy 0.000 claims description 2
- 238000005096 rolling process Methods 0.000 claims description 2
- 210000004413 cardiac myocyte Anatomy 0.000 abstract description 6
- 230000024245 cell differentiation Effects 0.000 abstract description 3
- 208000010125 myocardial infarction Diseases 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 44
- 230000004069 differentiation Effects 0.000 description 39
- 230000014509 gene expression Effects 0.000 description 23
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 22
- 239000011787 zinc oxide Substances 0.000 description 21
- 238000012360 testing method Methods 0.000 description 19
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 17
- 239000004205 dimethyl polysiloxane Substances 0.000 description 17
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 16
- 102000007469 Actins Human genes 0.000 description 14
- 108010085238 Actins Proteins 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 239000000758 substrate Substances 0.000 description 10
- 102000001045 Connexin 43 Human genes 0.000 description 8
- 108010069241 Connexin 43 Proteins 0.000 description 8
- -1 SMAD Proteins 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000003757 reverse transcription PCR Methods 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 7
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 7
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 7
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 6
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 6
- 102000010825 Actinin Human genes 0.000 description 5
- 108010063503 Actinin Proteins 0.000 description 5
- 102100031790 Myelin expression factor 2 Human genes 0.000 description 5
- 101710107751 Myelin expression factor 2 Proteins 0.000 description 5
- 239000010408 film Substances 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 3
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 description 3
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 3
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 3
- 101150114527 Nkx2-5 gene Proteins 0.000 description 3
- 102100021380 Transcription factor GATA-4 Human genes 0.000 description 3
- 101100460507 Xenopus laevis nkx-2.5 gene Proteins 0.000 description 3
- 229960002756 azacitidine Drugs 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 210000004292 cytoskeleton Anatomy 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000013013 elastic material Substances 0.000 description 3
- 230000005684 electric field Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 102000010970 Connexin Human genes 0.000 description 2
- 108050001175 Connexin Proteins 0.000 description 2
- 101001009079 Homo sapiens Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- 102100027391 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 Human genes 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 210000001650 focal adhesion Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000001027 hydrothermal synthesis Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000035990 intercellular signaling Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- XIOUDVJTOYVRTB-UHFFFAOYSA-N 1-(1-adamantyl)-3-aminothiourea Chemical compound C1C(C2)CC3CC2CC1(NC(=S)NN)C3 XIOUDVJTOYVRTB-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BUOYTFVLNZIELF-UHFFFAOYSA-N 2-phenyl-1h-indole-4,6-dicarboximidamide Chemical compound N1C2=CC(C(=N)N)=CC(C(N)=N)=C2C=C1C1=CC=CC=C1 BUOYTFVLNZIELF-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 229910004613 CdTe Inorganic materials 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100027875 Homeobox protein Nkx-2.5 Human genes 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000632197 Homo sapiens Homeobox protein Nkx-2.5 Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 1
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 1
- 101100013973 Mus musculus Gata4 gene Proteins 0.000 description 1
- 108010023356 Nonmuscle Myosin Type IIA Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 101700032040 SMAD1 Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910007717 ZnSnO Inorganic materials 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002304 esc Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000000445 field-emission scanning electron microscopy Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 230000009067 heart development Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960004011 methenamine Drugs 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000003365 myofibril Anatomy 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002070 nanowire Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002207 thermal evaporation Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1384—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from adipose-derived stem cells [ADSC], from adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2527/00—Culture process characterised by the use of mechanical forces, e.g. strain, vibration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
Abstract
Description
본 발명은 전기·기계적 자극을 가하여 줄기세포를 심근세포로 분화시키는 방법에 관한 것이다.
The present invention relates to a method for differentiating stem cells into myocardial cells by applying electromechanical stimulation.
줄기 세포는 특정한 세포로 분화가 진행되지 않은 채 유지되다가 필요할 경우 분열, 복제하여 신경, 혈액, 연골, 근육 등 몸을 구성하는 모든 종류의 세포로 분화할 가능성을 가진, 각 세포로 분화(differentiation)되기 전 단계의 미분화 세포들을 총칭한다. 줄기세포는 세포분열이 정지된 분화된 세포와는 달리 세포분열에 의해 자신과 동일한 세포를 생산(self-renewal)하며 증식(proliferation)하는 특성이 있으며, 또한 분화 자극(미세환경)이 가해지면 특정 세포로 분화가 진행되는데 다른 환경 또는 다른 분화 자극에 의해 다른 세포로도 분화될 수 있어 분화에 유연성(plasticity)을 가지고 있는 것이 특징이다. Stem cells are differentiated into individual cells, which are maintained as they do not undergo differentiation into specific cells, and are capable of differentiating into all kinds of cells, such as nerves, blood, cartilage, and muscles, And the undifferentiated cells at the pre-stage. Unlike the differentiated cells in which the cell division is stopped, the stem cells are self-renewing and proliferate by the cell division, and when the differentiation stimulus (micro environment) is applied, It is characterized by plasticity in differentiation because it can be differentiated into other cells by different environment or differentiation stimulation.
최근에는 상기와 같은 줄기세포의 특징을 활용하여 전기적 자극(electric field) 혹은 기계적 자극(cyclic strain)을 이용한 심장의 미세환경 모사를 통한 중간엽 줄기세포의 심근분화 방법이 많이 사용되고 있다. 그러나, 전기장 혹은 전류를 사용한 전기적 자극만을 가하는 방법과, 기계적 자극만을 가하는 연구는 각각 존재하지만 분화 효율에서 한계가 있어, 개선의 여지가 있다.In recent years, a method of differentiating mesenchymal stem cells from myocardial cells through microenvironmental simulation of the heart using an electric field or a cyclic strain has been widely used by utilizing the above-described features of stem cells. However, there are methods of applying only electrical stimulation using an electric field or current, and studies of applying only mechanical stimulation, but there is a limit to the efficiency of differentiation and there is room for improvement.
한편, 심장질환은 선진국들에서 주된 사망원인으로 자리 잡고 있으며, 우리나라에서도 유병률이 빠른 속도로 증가하고 있는 추세이다. 현재 심근경색 및 비정상적인 심장발달을 치료하기 위한 다양한 시술들이 시행되고 있으나, 심근세포의 낮은 재생능력 때문에 완치에 많은 어려움이 있다.On the other hand, heart disease is the leading cause of death in developed countries and the prevalence rate is increasing rapidly in Korea. Currently, various procedures are performed to treat myocardial infarction and abnormal cardiac development, but there are many difficulties in curing due to the low regeneration ability of myocardial cells.
현재 심장질환 치료를 위해 가장 많이 시행되고 있는 시술은 장기 이식 및 동물 유래 조직으로 심장조직 일부를 치환하는 시술이다. 하지만 이러한 시술들은 장기 기증자의 확보 및 이종간 면역거부 반응 등의 문제가 있다.Currently, the most commonly performed procedures for treating heart disease are transplantation and replacement of part of the heart tissue with animal-derived tissue. However, these procedures have problems such as securing organ donors and rejecting immune rejection.
이러한 문제점을 해결하기 위해 많은 연구 그룹들이 심근세포의 이식을 통하여 심장의 기능을 회복시키는 방법에 관한 연구를 진행하고 있다. 심근세포의 이식에 이용될 세포를 획득하기 위한 방법으로는 성체줄기세포, 배아줄기세포 및 유도 만능줄기세포(Induced pluripotent stem cells: iPSC)를 분화시켜서 심근세포를 획득하는 것이 가장 일반적으로 제시되고 있는 방법이다. 그러나 배아줄기세포와 유도만능줄기세포는 공통적으로 양성종양(teratoma) 형성 위험이 문제가 되어 임상적용에 어려움을 겪고 있다.
To solve these problems, many research groups are conducting research on how to restore heart function through cardiac cell transplantation. As a method for acquiring cells to be used for cardiomyocyte transplantation, it is most commonly proposed to obtain myocardial cells by differentiating adult stem cells, embryonic stem cells and induced pluripotent stem cells (iPSC) Method. However, embryonic stem cells and inducible pluripotent stem cells (ESCs) commonly suffer from the risk of teratoma formation, making them difficult to apply in clinical applications.
본 발명은 상기와 같은 종래 기술의 한계를 해결하기 위해, 보다 효율적으로 줄기세포를 심근세포로 분화 유도시키는 방법을 제공하는 것을 목적으로 한다.
Disclosure of Invention Technical Problem [8] To overcome the limitations of the prior art as described above, it is an object of the present invention to provide a method for efficiently inducing differentiation of stem cells into cardiac myocytes.
상기 목적을 달성하기 위하여, 본 발명은 In order to achieve the above object,
압전성과 탄성을 동시에 갖는 지지체 상에 줄기세포를 접종하는 단계 및 Inoculating stem cells onto a support having both piezoelectricity and elasticity, and
상기 줄기세포가 접종된 지지체에 운동력을 가하여 줄기세포를 심근세포로 분화시키는 단계를 포함하는 줄기세포의 분화 방법을 제공한다.And a step of differentiating the stem cells into myocardial cells by applying a motility to the support on which the stem cells have been inoculated.
또한 본 발명은 상기 방법에 의해 줄기세포로부터 분화된 심근세포를 함유하는 심근세포-지지체 복합체를 제공한다. The present invention also provides a myocardial cell-support complex containing myocardial cells differentiated from stem cells by the above method.
기타 본 발명의 구현 예들의 구체적인 사항은 이하의 상세한 설명에 포함되어 있다.
Other details of the embodiments of the present invention are included in the following detailed description.
압전성과 탄성을 동시에 가지는 지지체(Piezoelectric and Elastic Substrate: PES)에 줄기세포를 접종 한 후 운동력을 가하여 전기적 자극과 기계적 자극을 동시에 발생시킴으로써 줄기세포를 심근세포로 분화시키는 본 발명의 방법은 심근세포의 생체 내 미세환경을 모사하여 분화 효율을 더욱 높일 수 있다. 따라서, 본 발명은 심근경색을 포함한 심혈관 질환의 치료 등 다양한 연구에 활용될 수 있다.
The method of the present invention for differentiating stem cells into myocardial cells by inoculating stem cells into a piezoelectric and elastic substrate (PES) having both piezoelectricity and elasticity, followed by generating electrical stimulation and mechanical stimulation at the same time, It is possible to further enhance the differentiation efficiency by simulating in vivo microenvironment. Therefore, the present invention can be applied to various studies such as treatment of cardiovascular diseases including myocardial infarction.
도 1은 심장의 두 가지 미세환경, 전기적 신호와 기계적 신호를 보여주는 모식도이다.
도 2는 본 발명에 따라 PES를 이용하여 중간엽 줄기세포를 심근분화시키는 과정에 대한 모식도이다.
도 3은 본 발명에 일 실시예에 따라 PES의 굴신(屈伸) 및 신축(伸縮)운동이 가능한 세포 배양장치의 개략적인 구성도이다.
도 4는 PES의 제조과정 보여주는 모식도이다.
도 5는 실시예에서 사용된 (a)산화 아연(ZnO) 나노로드의 SEM 이미지, (b)PES에 사용되는 단일 산화 아연나노로드의 SEM 이미지이다.
도 6 내지 도 9는 시험예 1에서 PES 벤딩시(굴신운동시) 전기적 특성을 나타낸다.
도 10은 시험예 1에서 기계적 자극에 대한 PES 내 ZnO 나노로드의 배열을 나타낸다.
도 11은 시험예 1에서 10일 동안 PES와 PDMS를 굴신운동 및 기계적 자극을 주었을 때의 영구 변형 프로필을 나타낸다.
도 12 내지 도 14는 시험예 1에서 PES에 굴신, 전기적 자극 및 기계적 자극을 가하였을 때의 세포독성에 대한 것이다.
도 15는 시험예 2에서 기계적 자극에 의한 hMSC의 배열을 F-action 염색으로 나타낸 것이다(청색 = 세포 핵, 스케일 바 = 30 μm).
도 16 내지 18은 시험예 3 내지 5에 따라 전기적 자극과 기계적 자극에 의한 hMSC의 심근분화 향상을 평가한 것이다.
도 19는 전기적 자극 및 기계적 자극에 따른 hMSC의 심근분화 메커니즘의 모식도이다.
도 20은 시험예 6의 RT-PCR 방법에 의한 BMP-4, IGF, VEGF 및 TGF-β의 발현 평가 결과이다.
도 21은 시험예 3의 웨스턴 블롯 방법에 의한 p38, SMAD, FAK, ERK1/2의 발현을 나타낸다.1 is a schematic diagram showing two microenvironments of the heart, an electrical signal and a mechanical signal.
FIG. 2 is a schematic diagram illustrating a process of differentiating mesenchymal stem cells into myocardial cells using PES according to the present invention.
3 is a schematic diagram of a cell culture apparatus capable of bending and stretching (stretching and contracting) a PES according to an embodiment of the present invention.
4 is a schematic diagram showing a manufacturing process of PES.
5 is a SEM image of (a) zinc oxide (ZnO) nano-rods used in the examples, and (b) SEM images of single zinc oxide nanorods used in PES.
Figs. 6 to 9 show electrical characteristics at the time of PES bending (bending motion) in Test Example 1. Fig.
10 shows the arrangement of ZnO nanorods in the PES for mechanical stimulation in Test Example 1. FIG.
Fig. 11 shows the permanent strain profile when subjected to 10 days of PES and PDMS bending and mechanical stimulation in Test Example 1. Fig.
FIGS. 12-14 relate to cytotoxicity when subjected to PES, electrical stimulation and mechanical stimulation in Test Example 1. FIG.
15 shows the arrangement of hMSCs by mechanical stimulation in Test Example 2 with F-action staining (blue = cell nucleus, scale bar = 30 μm).
Figures 16 to 18 show the improvement of myocardial differentiation of hMSCs by electrical stimulation and mechanical stimulation according to Test Examples 3 to 5.
19 is a schematic diagram of a mechanism of myocardial differentiation of hMSC according to electrical stimulation and mechanical stimulation.
20 shows the results of evaluation of expression of BMP-4, IGF, VEGF and TGF-? By the RT-PCR method of Test Example 6. Fig.
21 shows the expression of p38, SMAD, FAK and ERK1 / 2 by the Western blot method of Test Example 3. Fig.
본 발명은 다양한 변환을 가할 수 있고 여러 가지 실시예를 가질 수 있는 바, 특정 실시예들을 도면에 예시하고 상세한 설명에 상세하게 설명하고자 한다. 그러나, 이는 본 발명을 특정한 실시 형태에 대해 한정하려는 것이 아니며, 본 발명의 사상 및 기술 범위에 포함되는 모든 변환, 균등물 내지 대체물을 포함하는 것으로 이해되어야 한다. 본 발명을 설명함에 있어서 관련된 공지 기술에 대한 구체적인 설명이 본 발명의 요지를 흐릴 수 있다고 판단되는 경우 그 상세한 설명을 생략한다.BRIEF DESCRIPTION OF THE DRAWINGS The present invention is capable of various modifications and various embodiments, and specific embodiments are illustrated in the drawings and described in detail in the detailed description. It is to be understood, however, that the invention is not to be limited to the specific embodiments, but includes all modifications, equivalents, and alternatives falling within the spirit and scope of the invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, the present invention will be described in detail with reference to the accompanying drawings.
본 명세서에서 층, 막, 필름, 기판 등의 부분이 다른 부분 '위에' 또는 '상에' 있다고 할 때, 이는 다른 부분 '바로 위에' 있는 경우뿐 아니라 그 중간에 또 다른 부분이 있는 경우도 포함한다. 반대로 층, 막, 필름, 기판 등의 부분이 다른 부분 '아래에' 있다고 할 때, 이는 다른 부분 '바로 아래에' 있는 경우뿐 아니라 그 중간에 또 다른 부분이 있는 경우도 포함한다. It will be understood that when a layer, film, film, substrate, or the like is referred to herein as being "on" or "on" another part, it also includes the case where there is another part in the middle, do. On the contrary, when a portion such as a layer, a film, a film, a substrate, or the like is referred to as being 'under' another portion, it includes not only a case where the other portion is 'directly below' but also a case where there is another portion in between.
이하에서는 본 발명을 구체적으로 설명한다. Hereinafter, the present invention will be described in detail.
본 발명에 따른 줄기세포 분화 방법은 The stem cell differentiation method according to the present invention comprises
압전성과 탄성을 동시에 갖는 지지체(PES) 상에 줄기세포를 접종하는 단계 및 Inoculating stem cells onto a support (PES) having both piezoelectricity and elasticity, and
상기 줄기세포가 접종된 지지체에 운동력을 가하여 줄기세포를 심근세포로 분화시키는 단계를 포함하는 것을 특징으로 한다. And applying a mobility to the support on which the stem cells are inoculated to differentiate the stem cells into myocardial cells.
본 명세서에서 '탄성' 은 힘을 가하면 형태가 변형되지만 힘을 제거하면 원래 형태로 돌아오는 성질을 의미한다. In the present specification, 'elasticity' refers to a property that deforms when a force is applied, but returns to its original shape when a force is removed.
또, 본 명세서에서 '운동력' 또는 '운동에너지' 는 굴곡, 인장, 신축 등과 같이 물리적 변화를 야기할 수 있는 자극을 의미하며, 그 수단이나 방식을 가리지 않는다.In the present specification, 'motility force' or 'kinetic energy' refers to a stimulus that may cause physical changes such as bending, stretching, and contraction, and does not discriminate the means or the method.
바람직한 구현예에 따르면, 상기 운동력은 굴신(屈伸) 운동 및 신축(伸縮) 운동 중 어느 하나이거나 두 가지가 동시에 가해지는 것일 수 있다. 굴신운동은 굽혔다 펴지는 운동, 신축운동은 늘어났다가 원래 상태로 복귀하거나 수축하는 운동을 의미한다. PES는 탄성을 보유하기 때문에 이러한 운동이 가능하다.According to a preferred embodiment, the movement force may be either one of a bending and stretching motion and a stretching motion, or both. Exercise means bending, stretching, and stretching movements, which move back to their original state or contract. This movement is possible because the PES has elasticity.
또한, 본 발명에 따른 줄기세포 분화방법은 전기적 에너지와 기계적 에너지를 줄기세포에 동시에 가함으로써 분화를 촉진하는바, 상기 지지체에 가해지는 굴신 운동 또는 신축 운동은 지지체의 압전성을 이용하여 전기적 에너지 및 기계적 에너지를 발생시키는 것일 수 있다.In addition, the method of differentiating stem cells according to the present invention promotes differentiation by simultaneously applying electrical energy and mechanical energy to the stem cells, and the stretching motion or the stretching motion applied to the supporter can be carried out by using the piezoelectricity of the supporter, It may be to generate energy.
상기 전기적 에너지는 상기 지지체를 0.1 ~ 10 Hz 빈도로 굽혔다 펴주는 운동에 의해 0.1 ~ 10 V의 전압을 발생시키는 것일 수 있다. 바람직하게는 0.1 ~ 5 Hz의 빈도로 0.5 ~ 5V의 전압을 발생시킬 수 있다. The electrical energy may be one that generates a voltage of 0.1 to 10 V by bending and rolling the support at a frequency of 0.1 to 10 Hz. A voltage of 0.5 to 5 V can be generated at a frequency of preferably 0.1 to 5 Hz.
상기 기계적 자극은 상기 지지체를 0.1 ~ 10 Hz 빈도로 원래 길이 대비 1 ~ 20%의 길이를 늘렸다가 수축시키는 운동에 의해 발생시키는 것일 수 있다. 바람직하게는 0.1 내지 5 Hz의 빈도로 지지체 원래 길이 대비 1 ~ 10%의 길이를 늘렸다가 수축시키는 운동에 의해 전압을 발생시킬 수 있다.The mechanical stimulation may be generated by stretching the support by a length of 1 to 20% of the original length at a frequency of 0.1 to 10 Hz and contracting the support. The voltage can be generated by increasing the length of 1 to 10% of the original length of the support by a frequency of preferably 0.1 to 5 Hz and shrinking it.
바람직한 실시예에 따르면, 상기 접종된 줄기세포는 지지체에 가해지는 운동력의 방향과 수직한 방향으로 배열될 수 있다. According to a preferred embodiment, the inoculated stem cells can be arranged in a direction perpendicular to the direction of the motive force applied to the support.
상기 줄기세포는 지방 줄기세포, 중간엽 줄기세포, 골수 줄기세포, 제대혈 줄기세포, 신경줄기세포 및 유도만능 줄기세포로 구성된 군으로부터 선택되는 것일 수 있다.The stem cells may be selected from the group consisting of adipose stem cells, mesenchymal stem cells, bone marrow stem cells, cord blood stem cells, neural stem cells and induced pluripotent stem cells.
예를 들어, 중간엽 줄기세포(mesenchymal stem cell, MSC)는 다능성 미분화 세포로 태아의 중배엽에서 유래된 결합조직이며, 형태적으로 망상섬유와 비특이적 세포의 성긴 집합체를 포함한 기질세포로 미세환경에 따라서, 결합조직, 골, 연골, 림프관, 혈관 등의 기관으로 분화 가능하다.For example, mesenchymal stem cells (MSCs) are pluripotent undifferentiated cells derived from mesenchymal cells of the fetus and are morphologically stromal cells containing spongy fibers and spongy aggregates of nonspecific cells. Thus, it can be differentiated into organs such as connective tissue, bone, cartilage, lymphatic vessels, and blood vessels.
도 1은 심장의 두 가지 미세환경, 전기적 신호와 기계적 신호를 보여주는 모식도이다. 즉 심장은 전기적 자극(electric field)과 기계적 자극(cyclic strain) 이 가해짐으로써 심근세포 분화가 촉진된다. 심근 세포의 분화 과정은 실시예에서 구체적으로 설명한다. 1 is a schematic diagram showing two microenvironments of the heart, an electrical signal and a mechanical signal. In other words, the cardiomyocyte differentiation is promoted by the application of electric field and mechanical stimulus (cyclic strain). The differentiation process of myocardial cells will be specifically described in the examples.
이에 본 발명에서는, 중간엽 줄기세포를 심근세포로 분화시키기 위한 배양 지지체로서 도 2에 도시된 바와 같이 전기적 신호 및 기계적 신호를 동시에 발생시키거나 인가할 수 있는 PES를 사용하였다.In the present invention, as a culture supporter for differentiating mesenchymal stem cells into myocardial cells, a PES capable of simultaneously generating or applying an electrical signal and a mechanical signal is used as shown in FIG.
PES는 예를 들어 도 3에 도시된 장치를 이용하여 반복적인 스트레칭이나 벤딩됨으로써 전기적 자극 및 기계적 자극을 지지체에 접종된 줄기세포에 전달할 수 있다.The PES can be repeatedly stretched or bent using, for example, the device shown in FIG. 3, to deliver electrical stimulation and mechanical stimulation to the stem cells inoculated to the support.
구체적으로, 도 3 장치의 모터의 운동이 세포 배양부에 위치한 PES에 전해지고, 이에 의하여 PES가 굴신(屈伸, bending)운동을 하며 PES의 압전 물질을 자극하여 전기적 신호를 발생시키고, PES의 신축(伸縮, stretching) 운동을 통한 탄성 물질에 의한 기계적 신호를 발생시 킬 수 있다.Specifically, the motion of the motor of the apparatus of FIG. 3 is transmitted to the PES located in the cell culture section, thereby causing the PES to bend and bend, stimulating the piezoelectric material of the PES to generate an electrical signal, Stretching, stretching) motion of the elastic material.
바람직한 구현예에 따르면, 도 4에 도시된 바와 같이, PES는 탄성층과 압전물질층이 1회 이상, 바람직하게는 2회 이상 교대로 적층된 구조를 가질 수 있다. 이때, 최외곽층은 탄성층이 되도록 하는 것이 바람직하다. According to a preferred embodiment, as shown in FIG. 4, the PES may have a structure in which the elastic layer and the piezoelectric material layer are alternately laminated one or more times, preferably two or more times. At this time, it is preferable that the outermost layer is an elastic layer.
일 구현예에 따르면, 상기 지지체는 According to one embodiment, the support comprises
제 1 탄성층, 제 2 탄성층, 및 상기 제 1 탄성층과 제 2 탄성층 사이에 배열된 압전물질층을 포함하는 단위 구조를 갖는 것일 수 있다. And a piezoelectric material layer arranged between the first elastic layer and the second elastic layer. The first elastic layer, the second elastic layer, and the piezoelectric material layer are disposed between the first elastic layer and the second elastic layer.
상기 압전물질은 ZnO, BaTiO3 및 NaNBO3 를 포함하는 압전 물질 중 하나 이상일 수 있으나, 이에 한정되는 것은 아니다. 즉 ZnO는 대표적인 압전 재료의 한 가지 예로서, 본 발명은 이에 제한되지 않으며, 외부의 기계적인 힘을 전위로 바꿀 수 있는 압전 재료이기만 하면, 본 발명에 적용될 수 있다. 예컨대, ZnO, ZnSnO3, GaN, Te, CdTe, CdSe, KNbO3, NaNbO3, InN, PVDF, PVDF-TrFE 등의 압전재료를 이용할 수도 있다.The piezoelectric material may be at least one of piezoelectric materials including ZnO, BaTiO 3 and NaNBO 3 , but is not limited thereto. That is, ZnO is an example of a typical piezoelectric material, and the present invention is not limited thereto, and can be applied to the present invention as long as it is a piezoelectric material capable of converting an external mechanical force into electric potential. For example, ZnO, ZnSnO 3, GaN, it is also possible to use a piezoelectric material such as Te, CdTe, CdSe, KNbO 3 ,
또한, 상기 압전물질층은 복수의 압전물질 나노로드를 포함하여 이루어질 수 있다. 또, 상기 압전물질 나노로드는 이축 성장 압전물질 나노로드일 수 있다. The piezoelectric material layer may include a plurality of piezoelectric material nanorods. The piezoelectric material nanorod may be a biaxially grown piezoelectric material nano-rod.
또, 상기 압전물질 나노로드는 일방향으로 배열되어 압전물질층을 형성할 수 있으며, 특히 일방향 단일층으로 배열되어 압전물질층을 형성할 수 있다.In addition, the piezoelectric material nano-rods may be arranged in one direction to form a piezoelectric material layer. In particular, the piezoelectric material nano-rods may be arranged in a unidirectional single layer to form a piezoelectric material layer.
본 명세서에서 나노로드라는 용어는 당업계에서 당업자가 통상적으로 사용하고 있는 용어로서, 보통 종횡비(aspect ratio)가 10 이하인 상태의 로드를 의미할 수 있으며, 또한, 경우에 따라서, 당업계에서는 나노는 그 크기와 관련하여 약 100 nm 이하인 것을 지칭하기도 한다. 이와 같이, 나노로드는 당업계에서 당업자가 통상적으로 사용하고 있는 기술적 의미를 갖고 있는 물질로서 해석된다는 점에 유의하여야 한다. 본 발명의 일 실시예에서 사용된 ZnO 나노로드는 길이가 약 2.5~3 ㎛이고, 직경은 약 200~250 nm 이었다. 이러한 작은 크기의 1차원 나노물질은 외부로부터의 작은 기계적 에너지(굽힘이나 흔들림)에 의해 쉽게 격자 변형이 유도될 수 있는 특징을 갖고 있다.As used herein, the term nanorod is a term commonly used by those skilled in the art, and may generally mean a rod with an aspect ratio of 10 or less, and, in some cases, And may be referred to as about 100 nm or less with respect to the size thereof. As such, it should be noted that the nanorod is interpreted as a material having the technical meaning commonly used by those skilled in the art. The ZnO nanorods used in one embodiment of the present invention were about 2.5 to 3 mu m in length and about 200 to 250 nm in diameter. These small-sized one-dimensional nanomaterials are characterized in that lattice strain can be easily induced by small mechanical energy (bending or shaking) from the outside.
이후 설명되는 실시예에서는 나노로드, 구체적으로 이축 성장 나노로드를 사용하여 압전전위를 생성하였지만, 본 발명은 이에 제한되지 않는다. 즉, 일축 성장 나노로드 역시 채용할 수 있으며, 압전 특성을 갖는 물질로서, 나노크기를 갖는 필름의 형태, 나노와이어 형태 등의 것을 채용할 수도 있다. 또한, 실시예에서 채용한 이축 성장 나노로드를 수열합성법에 의해 제조하는 것을 예시하였지만, 본 발명은 이에 제한되지 않는다. 즉, 대량으로 합성하는 경우에는 수열합성법을 이용하지만, 소량의 높은 결정화도를 갖는 나노로드를 형성하기 위하여, CVD법을 이용할 수도 있다.In the embodiments described hereinafter, the nano-rods, specifically, biaxially-grown nano-rods are used to generate the piezoelectric potential, but the present invention is not limited thereto. That is, uniaxially grown nano-rods can also be employed. As the material having piezoelectric properties, a nano-sized film shape, a nanowire shape, or the like may be employed. In addition, the biaxially grown nano-rods employed in the examples were produced by the hydrothermal synthesis method, but the present invention is not limited thereto. That is, hydrothermal synthesis is used in the case of mass synthesis, but CVD may be used to form a nanorod having a small amount of high crystallinity.
상기 탄성층은 외부로부터 인가되는 기계적 에너지를 상기 압전물질층에 전달할 수 있는 재료로 이루어지는 것이 바람직하다. The elastic layer is preferably made of a material capable of transmitting mechanical energy applied from the outside to the piezoelectric material layer.
또한, 상기 탄성층은 상기 압전물질층으로부터 발생되는 압전 전위를 접종된 줄기세포에 전달할 수 있는 재료로 이루어진 것이 바람직하다.In addition, it is preferable that the elastic layer is made of a material capable of transmitting the piezoelectric potential generated from the piezoelectric material layer to the inoculated stem cells.
바람직한 실시예에 따르면, 탄성층은 PDMS(polydimethylsiloxane)를 포함하는 재료로 이루어질 수 있으나, 이에 한정되지 않으며 세포 적합성이나 유전상수를 갖고 있는 탄성 재료라면 제한없이 사용할 수 있다. 즉, 유전 상수를 갖고 있어 압전 재료로부터 발생되는 압전 전위를 전달하기 쉬운 유전물질을 본 발명에 적용할 수 있으며, 외부로부터 인가되는 기계적 에너지를 압전 재료에 큰 손실 없이 전달할 수 있으면 바람직하다.According to a preferred embodiment, the elastic layer may be made of a material containing PDMS (polydimethylsiloxane), but is not limited thereto and any elastic material having cell suitability or dielectric constant can be used without limitation. That is, a dielectric material having a dielectric constant and easy to transmit a piezoelectric potential generated from the piezoelectric material can be applied to the present invention, and it is preferable that mechanical energy applied from the outside can be transmitted to the piezoelectric material without loss.
본 발명의 바람직한 실시예에 따르면, 중간엽 줄기세포에 전기적 자극과 기계적 자극을 동시에 주었을 때 심근세포로의 분화효율이 증가함을 알 수 있다.According to a preferred embodiment of the present invention, when the electrical stimulation and the mechanical stimulation are simultaneously given to the mesenchymal stem cells, the efficiency of differentiation into myocardial cells is increased.
전술한 방법에 의해 줄기세포로부터 분화된 심근세포는 심근세포-지지체 복합체로서 다양한 용도에 활용될 수 있다.
The myocardial cells differentiated from the stem cells by the above-described method can be used for various uses as myocardial cell-support complexes.
이하에서는, 첨부 도면을 참조하여 본 발명의 실시예를 설명한다. 이하의 설명에 있어서, 당업계에 이미 알려진 기술적 구성에 대한 설명은 생략한다. 예컨대, 일축 나노로드, 이축 성장 나노로드를 합성/제조하는 방법, 나노로드를 러빙(rubbing) 공정을 통해 정렬하는 공정은 액정 정렬과 관련하여 이미 널리 알려진 공정이므로, 그 사세한 설명은 생략한다. 이러한 설명을 생략하더라도, 당업자라면 이하의 설명을 통해 본 발명에 따라 제시되는 세포 지지체의 구성, 그 기능 등을 쉽게 이해할 수 있을 것이다.
Hereinafter, embodiments of the present invention will be described with reference to the accompanying drawings. In the following description, the description of technical constructions already known in the art will be omitted. For example, the uniaxial nano-rod, the method of synthesizing / manufacturing the biaxially grown nano-rods, and the process of aligning the nano-rods through the rubbing process are well-known processes related to the liquid crystal alignment, so detailed description thereof is omitted. Even if these explanations are omitted, those skilled in the art will readily understand the constitution of the cell support, its function, and the like, which are presented according to the present invention through the following description.
<제조예 1> 산화아연 나노로드(ZnO NRs) 분말의 준비PREPARATION EXAMPLE 1 Preparation of zinc oxide nano-rods (ZnO NRs) powder
산화아연 나노로드 분말은 습식화학방법(wet chemical method)을 이용하여 준비하였다.The zinc oxide nanorods powders were prepared by a wet chemical method.
0.42g의 징크 나이트레이트 헥사하이드레이트(zinc nitrate hexahydrate)(Zn(NO3)2ㆍ6H2O, ≥99.0%)(Sigma Aldrich)를 100 mL의 탈이온수에 용해하고, 0.24g의 HMTA(헥사메틸렌테트라민, Sigma Aldrich)를 100 mL의 탈이온수에 별도로 용해하여(모두 실온에서), 두 개의 전구체 용액을 준비하였다. 85℃에서 교반하면서, 징크 전구체 용액을 25분 동안 2 mL/h의 주입 속도로 시린지 펌프를 통해 HMTA 용액 내로 연속하여 주입하였으며, 상기 프로세스를 5분 후에 종결하였다. 원심 분리 후에, 응집된 나노로드(flocculated nanorods)를 부유물로부터 분리하여 탈이온수로 3번 세정하여, 미반응 Zn2+및 다른 이온들을 제거하였다. 최종 석출물을 80℃에서 건조하였고, 진공 중에서 2시간 동안 400℃에서 어닐링 처리하여 결정성을 향상시켜, 최종적으로 이축 성장 ZnO 나노로드 파우더를 합성하여 준비하였다.
0.42 g of zinc nitrate hexahydrate (Zn (NO 3 ) 2 .6H 2 O, ≥99.0%) (Sigma Aldrich) was dissolved in 100 mL of deionized water and 0.24 g of HMTA (hexamethylene Tetramine, Sigma Aldrich) were separately dissolved in 100 mL of deionized water (all at room temperature) to prepare two precursor solutions. With stirring at 85 DEG C, the zinc precursor solution was continuously injected into the HMTA solution via a syringe pump at an injection rate of 2 mL / h for 25 minutes, and the process was terminated after 5 minutes. After centrifugation, the flocculated nanorods were separated from the suspension and washed three times with deionized water to remove unreacted Zn 2+ and other ions. The final precipitate was dried at 80 占 폚 and annealed at 400 占 폚 for 2 hours in vacuum to improve the crystallinity and ultimately to prepare a biaxially grown ZnO nano-rod powder.
<제조예 2> 압전성과 탄성을 가진 재료(Piezoelectric and Elastic Substrate: PES)의 제작 PREPARATION EXAMPLE 2 Preparation of Piezoelectric and Elastic Substrate (PES) Having Piezoelectricity and Elasticity
도 4에 개시된 압전성과 탄성을 가진 재료(PES)는 탄성을 가지는 PDMS(polydimethyl-siloxane)(두께 약 3 mm) 사이에 압전성을 가지는 복수의 산화아연 나노로드(ZnO NRs)가 정렬된 구조가 복수개 적층되어 있으며, 그 제조과정은 대한민국 특허등록 10-1497338호를 참조할 수 있다. The piezoelectric and elastic material (PES) disclosed in Fig. 4 has a structure in which a plurality of zinc oxide nano-rods (ZnO NRs) having piezoelectricity are arranged between elasticity polydimethyl-siloxane (PDMS) And the manufacturing process thereof can be referred to Korean Patent Registration No. 10-1497338.
산화 아연 나노로드의 형태학적 특징을 JEOL JSM-7000F 전계 방출형 주사현미경(FESEM, Jeol Ltd, Akishima, Tokyo, Japan; 15 kV)을 이용하여 분석하였다(도 5 참조).The morphological characteristics of the zinc oxide nanorods were analyzed using a JEOL JSM-7000F field emission scanning microscope (FESEM, Jeol Ltd., Akishima, Tokyo, Japan;
PDMS 블록과 러빙 공정(rubbing process)용 기판은 10:1의 중량비로 경화제와 같이 준비하였다(Sylgard 184, Dow corning Chemicals). PDMS 기판상에 PDMS 블록과 함께 단방향 러빙 공정을 통하여 산화 아연 나노로드 단일 층을 형성하고(도 5(a) 참조), 산화 아연 나노로드 단일 층 상에 PDMS를 코팅하기 위하여 처리되지 않은 PDMS를 헥산에 1:1의 중량비로 희석하였다. The PDMS block and the substrate for the rubbing process were prepared with a curing agent in a weight ratio of 10: 1 (Sylgard 184, Dow Corning Chemicals). A single layer of zinc oxide nanorods was formed on the PDMS substrate with a PDMS block through a unidirectional rubbing process (see Fig. 5 (a)), and the untreated PDMS was coated onto a single layer of zinc oxide nano- At a weight ratio of 1: 1.
상기 희석된 PDMS를 산화아연 나노로드 단일 층을 가지는 PDMS 기판에 가하여 3,000 rpm으로 30 초간 스핀코팅(spin-coating)하고, 공기 중의 85℃ 핫 플레이트 에서 30분간 처리하였다.The diluted PDMS was applied to a PDMS substrate having a single layer of zinc oxide nanorods, spin-coated at 3,000 rpm for 30 seconds, and treated on a hot plate at 85 ° C for 30 minutes.
상기와 같은 공정을 5번 반복하여 3V의 전기적 신호를 내는 5겹의 산화아연 나노로드층(압전물질층)을 가지는 PES(Piezoelectric and Elastic Substrate)를 제작하였다.
The above process was repeated 5 times to fabricate a PES (Piezoelectric and Elastic Substrate) having a 5-fold zinc oxide nano-rod layer (piezoelectric material layer) which gives an electrical signal of 3V.
<시험예 1> PES(Piezoelectric and Elastic Substrate)의 특징 분석Test Example 1 Characteristic Analysis of PES (Piezoelectric and Elastic Substrate)
상기 제조예 1에서 제조된 PES의 전기적 특성을 평가하기 위하여, 은 전극(200 nm)을 열증착법(thermal evaporation)으로 PES의 상부 및 하부에 증착하여 얻은 소자를 3 mm 두께의 PDMS 기판 상에 장착한 후, 전압 및 전류 신호를 측정하였다.In order to evaluate the electrical properties of the PES prepared in Preparation Example 1, a silver electrode (200 nm) was deposited on the upper and lower sides of the PES by thermal evaporation, and the resulting device was mounted on a 3 mm thick PDMS substrate After that, voltage and current signals were measured.
도 6 내지 도 9는 길이 5 cm의 PES 를 20 mm 곡률반경으로 벤딩(굴신운동)시 전기적 특성을 나타내며, 전류와 전압은 각각 피코암메터(picoammeter, Keithley 6485, Keithely Instruments, Cleveland, OH, USA)와 일렉트로미터/고저항미터(electrometer/high resistance meter, Keithley 6517, Keithley Instruments)를 이용하여 측정하였다.FIGS. 6 to 9 show electrical characteristics when the PES having a length of 5 cm was bent at a radius of curvature of 20 mm (flexing motion). The current and the voltage were measured using a picoammeter (Keithley 6485, Keithley Instruments, Cleveland, ) And an electrometer / high resistance meter (Keithley 6517, Keithley Instruments).
구체적으로, 도 6은 포워드 연결했을 때 PES에서 생성되는 개방회로 전압, 도 7은 리버스 연결했을 때 PES에서 생성되는 개방회로 전압, 도 8은 포워드 연결했을 때 PES에서 생성되는 단락회로 전류 밀도, 도 9는 리버스 연결했을 때 PES에서 생성되는 단락회로 전류 밀도를 나타낸다. Specifically, FIG. 6 shows the open circuit voltage generated in the PES when connected in the forward direction, FIG. 7 shows the open circuit voltage generated in the PES when connected in reverse, FIG. 8 shows the short circuit current density generated in the PES 9 represents the short circuit current density generated at the PES when reverse connected.
PES의 산화아연 나노로드의 정렬은 5개의 랜덤 사이트에 대하여 굴신자극 0일과 10일 후의 사진을 광학현미경(BX41, Olympus, Tokyo, Japan)을 이용하여 촬영하고 평가하고, 이미지 제이(Image J software, National Institute of Health, Bethesda, MD, USA)를 이용하여 분석하였다. 도 10은 0일과 10일의 굴신운동 및 기계적 자극에 대한 PES 안의 ZnO NRs의 배열을 보여준다.Alignment of zinc oxide nanorods of PES was performed by photographing and evaluating photographs of 0 random and 10 day post-stimulation at 5 random sites using an optical microscope (BX41, Olympus, Tokyo, Japan) National Institutes of Health, Bethesda, Md., USA). Figure 10 shows the arrangement of ZnO NRs in PES for 0 day and 10 day flexion and mechanical stimulation.
PES 와 PDMS의 영구변형을 알아보기 위하여, 굴신자극 또는 굴신/신축 자극을 주기 전과 후의 길이를 측정하여 비교하였다. 도 11은 10일동안 PES와 PDMS를 굴신운동 및 기계적 자극을 주었을 때의 영구 변형 프로필을 나타낸다. To determine the permanent deformation of PES and PDMS, lengths before and after stimulation were compared and measured. Figure 11 shows the permanent strain profile when subjected to 10 days of PES and PDMS bending and mechanical stimulation.
시험예 1의 결과 ZnO NRs가 PDMS위에 단일 방향, 모노레이어로 배열 되어있는 것을 확인 할 수 있었으며, 5 cm 길이의 PES를 20 mm 곡률 반경으로 굴신 운동 시켰을 때 3V의 전기적 신호를 내는 것을 확인 할 수 있었다.
As a result of Test Example 1, it was confirmed that ZnO NRs were arranged on the PDMS in a unidirectional, monolayer arrangement. When the 5 cm PES was moved with a radius of curvature of 20 mm, an electrical signal of 3 V was obtained there was.
<실시예 1> PES를 이용한 중간엽 줄기세포의 심근분화 유도Example 1 Induction of Myocardial Differentiation of Mesenchymal Stem Cells Using PES
사람 중간엽 줄기세포(Human mesenchymal stem cells: hMSCs)(Lonza, Walkerxville, MD, USA)는 10%(v/v) FBS(etal bovine serum)(Gibco BRL)와 1%(v/v) penicillin/streptomycin(Gibco BRL)이 포함된 DMEM low glucose(Dulbecco's Modified Eagle Medium low glucose)(Gibco BRL, Gaithersburg, MD, USA)로 구성된 배지로 37℃, 5%(v/v)CO2 항온·항습 배양기에서 배양하였으며, 계대배양(passage) 6 회 이하인 hMSCs 세포만을 사용하였다.Human mesenchymal stem cells (hMSCs) (Lonza, Walkerxville, MD, USA) were inoculated with 10% v / v FBS (Gibco BRL) and 1% v / v penicillin / (v / v) CO 2 incubator at 37 ° C in a medium consisting of DMEM low glucose (Gibco BRL, Gaithersburg, MD, USA) containing streptomycin (Gibco BRL) , And only hMSCs cells with no more than 6 passage passages were used.
중간엽 줄기세포를 PES로 이루어진 세포 부착부에 약 5 x 104 cells/cm2 의 세포 농도로 씨딩(seeding)하고, 5-azacytidine(5-azaC )(6 μmol/L)을 처리하고 1일 동안 배양하였다. 도 3에 도시된 장치에, 줄기세포가 접종된 PES를 배치시킨 후, 약 10일간 굽혔다 펴주는 자극을 통해 전기적 신호를 발생시키고, 늘렸다 수축시키는 자극을 통해 기계적 신호를 발생시켜 PES에 부착된 중간엽 줄기세포에 자극을 주었다. 이때, 상기 전기적 자극은 1 Hz 빈도로 20 mm 곡률반경을 통해서 약 3V의 전기적 신호를 발생시키고, 상기 기계적 자극은 1 Hz 빈도로 기존의 길이대비 3 %의 길이를 늘렸다가 수축시켜줌으로써 기계적 자극을 발생 시켰으며, 세포 배양부의 세포 배양배지는 3일 간격으로 교환하였다. The mesenchymal stem cells were seeded at a cell density of about 5 x 10 4 cells / cm 2 in the cell attachment area of PES, treated with 5-azacytidine (5-azaC) (6 μmol / L) Lt; / RTI > In the apparatus shown in FIG. 3, after placing the PES inoculated with the stem cells, electrical signals are generated through the stimulation for about 10 days, and mechanical signals are generated through the stimulation that stretches and contracts, Stimulation of lobular stem cells. At this time, the electrical stimulation generates an electrical signal of about 3V through a radius of curvature of 20 mm at a frequency of 1 Hz, and the mechanical stimulation increases the length of 3% of the conventional length by 1 Hz and shrinks the mechanical stimulus And the cell culture medium of the cell culture was changed every 3 days.
한편, 산화아연의 생체적합성 및 안정성은 산화아연 나노와이어 농도 100μg/ml 이하에서 세포 독성이 없는 것으로 나타났다. On the other hand, the biocompatibility and stability of zinc oxide were not cytotoxic at concentrations of zinc oxide nanowires below 100 μg / ml.
다양한 자극에 대한 세포분화 정도를 알아보기 위하여 실험은 하기 표 1에 나타낸 것과 같이 자극을 통제하였다.
To determine the degree of cell differentiation for various stimuli, the stimulation was controlled as shown in Table 1 below.
(6μmol)
5-azaC5-acacytidine
(6 μmol)
5-azaC
(屈伸刺戟)
BendingA stimulus
(Bending and stretching stimulation)
Bending
(伸縮刺戟)
Cyclic StrainStretching stimulus
(Stretching stimulation)
Cyclic Strain
(PZ)PES
(PZ)
(PD)PDMS
(PD)
(세포배양접시)TCP
(Cell culture dishes)
도 12 내지 도 14는 PES에 굴신(bending), 전기적 자극 및 기계적 자극을 가하였을 때의 세포독성에 대한 것으로, 구체적으로 도 12는 caspase-3(화살표로 표시된 붉은점)의 형광면역염색법에 의한 hMSC의 세포 사멸 기작에 대한 평가(청색=핵, 스케일 바 = 100 μm, PD=PDMS, PZ=PES), 도 13은 caspase-3에 대한 RT-PCR 결과, 도 14는 BCL-2 및 p53에 대한 RT-PCR 결과를 나타낸다. 이러한 결과에 따르면 PES 자체, PES 굴신에 의해 발생되는 전기적 자극, 굴신운동(Bending) 및 신축운동(CS)에 의한 세포독성효과가 나타나지 않음을 알 수 있다.
12 to 14 show cytotoxicity when bending, electrical stimulation and mechanical stimulation are applied to PES. Specifically, FIG. 12 shows the results of fluorescence immunoassay of caspase-3 (red dot indicated by an arrow) Fig. 14 shows the results of RT-PCR for caspase-3, Fig. 14 shows the results of BCL-2 and p53 (Fig. The RT-PCR results are shown in Fig. These results show that PES itself, CES induced by electric stimulation, bending and stretching motion (CS) generated by PES evolving does not appear.
<시험예 2> 팔로이딘 염색법에 의한 심근분화 유도 중간엽 줄기세포의 F-액틴 면역 염색 Test Example 2 Induction of Myocardial Differentiation by Paloidine Staining F-Actin Immunostaining of Mesenchymal Stem Cells
F-액틴(filamentous actin)은 세포의 형태를 유지하거나 형태를 변화시키거나 세포내의 물질 이동을 담당하고 있는 세포골격을 구성하는 섬유 중 하나로, 근원섬유의 구조를 형성할 뿐만 아니라 미오신과 상호반응하여 근수축에 직접 관여하는 것으로 팔로이딘 염색법(Phalloidin staining)을 이용하여 상기 표 1의 비교예 및 실시예의 중간엽 줄기세포의 F-액틴 염색을 통하여 세포의 일렬 배열을 확인하였다.F-Actin (filamentous actin) is one of the fibers that constitute the cytoskeleton that maintains the shape of the cell, changes the morphology or transfers the substance in the cell. It forms not only the structure of the myofibril but also the interaction with myosin A series of cells were confirmed through F-actin staining of mesenchymal stem cells of Comparative Examples and Examples in Table 1 using phalloidin staining directly involved in muscle contraction.
중간엽 줄기세포의 F-액틴의 팔로이딘 염색은 액틴사이토스캘레톤(Actin Cytoskeleton) 과 포칼어드히젼 염색 키트(Focal adhesion staining kit)(FAK100, Millipore)을 이용하여 하였으며, 염색된 F-액틴의 배열은 Image J software(National Institute of Health)를 사용하여 확인 하였다.Actin cytoskeleton and Focal adhesion staining kit (FAK100, Millipore) were used to stain Paloidin of F-actin of mesenchymal stem cells. Staining of F-actin of stained F-Actin was performed using Actin Cytoskeleton and Focal adhesion staining kit Arrangements were confirmed using Image J software (National Institute of Health).
도 15는 팔로이딘 염색법으로 염색한 상기 실시예와 비교예의 중간엽 줄기세포의 F-액틴 배열을 나타낸 것으로, 도 15의 결과에 의하면 세포는 PES를 늘리고 수축 시키는 방향과 수직한 방향으로 배열되는 경향성을 보였다. 이는 세포가 특정 기계적 신호를 받았을 때 그 자극을 최소화 시킬 수 있는 향으로 배열되려는 성질이 때문으로, 이러한 세포의 일렬 배열은 심근분화에 있어서 매우 중요한 요소이다. 일렬로 배열된 세포는 무작위로 배열된 세포에 비해, 세포간 신호 전달에 매우 중요한 역할을 하는 세포의 간극결합 단백질(예를 들어 connexin 43)이 더 많이 존재 하고, 분포하게 되기 때문이다. 특히, 심근의 경우 이러한 간극결합 단백질은 칼슘 이온의 전달 및 박동을 위한 핵심적인 요소이다.15 shows the F-actin arrangement of the mesenchymal stem cells of the above Examples and Comparative Examples stained with the Paloidine staining method. According to the results shown in Fig. 15, the cells had a tendency to be arranged in a direction perpendicular to the direction of increasing and contracting the PES Respectively. This is due to the tendency of the cells to be "oriented" to minimize their stimuli when they receive a specific mechanical signal, and this array of cells is a very important factor in myocardial differentiation. This is because cells arranged in a line are more likely to contain and distribute cell gap-binding proteins (for example, connexin 43), which play an important role in intercellular signaling, compared to randomly arranged cells. Particularly in the case of myocardium, this gap junction protein is a key factor for the delivery and pulsation of calcium ions.
상기 결과에서 기계적 신호에 의해 심근 분화된 중간엽 줄기세포는 심근 세포로서의 기능을 더 잘 수행할 수 있는 조건을 갖추었다고 할 수 있다.
These results suggest that mesenchymal stem cells differentiated by mechanical signals have better conditions to function as myocardial cells.
<시험예 3> 웨스턴 블롯에 의한 심근분화 유도 중간엽 줄기세포의 심근분화 관련 단백질의 발현량 비교 Test Example 3 Induction of myocardial differentiation by Western blotting Comparison of expression amounts of myocardial differentiation- related proteins of mesenchymal stem cells
웨스턴 블롯 방법을 이용하여 중간엽 줄기세포에서의 심근분화(cardiomyogenic differentiation), 심근분화에 관련된 분자신호(molecular signaling)를 관련된 단백질 마커를 통해 분석하였다.Using Western blotting, cardiomyogenic differentiation in mesenchymal stem cells and molecular signaling related to myocardial differentiation were analyzed through a related protein marker.
세포는 PBS(phosphate buffered saline, Gibco-BRL)을 이용하여 3번 세척한 후, SDS 샘플 버퍼(sodium dodecyl sulfate sample buffer)(62.5 mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, 50 mM dithiothreitol, 0.1% Bromophenol Blue)을 첨가하여 라이시스시킨 후에 수집하였다. 버퍼 속의 단백질은 4-10% SDS-PAGE (SDS-polyacrylamide gel)에 전기영동하고, 맴브레인(Millipore, Bedford, MA, USA)으로 전사하고, 1차 항체(primary antibodies against)로 Cx43, NKX2.5, MEF-2, GATA4, sarcomeric α-actinin, β-MHC, p38, pp38, SMAD, pSMAD, FAK, pFAK, ERK1/2, pERK1/2, 및 β-actin (Abcam, Cambridge, MA, USA)를 처리한 후 4℃에서 하룻밤 동안 반응시킨 후 세척하고, HRP(horseradish peroxidase)와 결합된 2차 항체를 처리하고 상온에서 50분동안 반응시켰다. 블롯은 ECL(enhanced chemiluminescence)(LumiGLO, KPL Europe, Guildford, UK)을 이용하여 디벨롭하였다.Cells were washed three times with PBS (phosphate buffered saline, Gibco-BRL) and resuspended in SDS sample buffer (62.5 mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, 50 mM dithiothreitol, 0.1% Bromophenol Blue). Proteins in the buffer were electrophoresed on 4-10% SDS-PAGE (SDS-polyacrylamide gel) and transferred to membranes (Millipore, Bedford, Mass., USA) and primary antibodies against Cx43, NKX2.5 , MEF-2, GATA4, sarcomeric alpha-actinin, beta-MHC, p38, pp38, SMAD, pSMAD, FAK, pFAK, ERK1 / 2, pERK1 / 2, and beta-actin (Abcam, Cambridge, After treatment, the cells were reacted overnight at 4 ° C, washed, treated with secondary antibody conjugated with horseradish peroxidase (HRP), and reacted at room temperature for 50 minutes. The blots were developed using ECL (enhanced chemiluminescence) (LumiGLO, KPL Europe, Guildford, UK).
도 16은 웨스턴 블롯 방법에 의한 NKX 2.5, MEF-2, GATA4, β-MHC, sarcomeric α-actinin 및 Cx43의 발현 향상을 나타내고, 도 21은 웨스턴 블롯 방법에 의한 p38, SMAD, FAK, ERK1/2의 발현을 나타낸다.FIG. 16 shows the expression of NKX 2.5, MEF-2, GATA4, β-MHC, sarcomeric α-actinin and Cx43 by the Western blot method and FIG. 21 shows the expression of p38, SMAD, FAK and ERK1 / 2 Lt; / RTI >
도 16에서 볼 수 있듯이, 전사 인자들로 구성되어 있는 초기 분화 인자인 NKX 2.5, MEF-2, GATA 4 및 후기 분화 인자인 β-MHC, sarcomeric α-actinin, connexin 43(Cx 43)을 비교한 결과, 5-azacytidine(5-azaC), 전기적 자극 및 기계적 자극을 주지 않고 TCP에서 세포 배양한 비교예 1에서는 단백질 발현이 거의 일어나지 않았고, 전기적 자극 및 기계적 자극 없이 5-azacytidine 처리만 한 비교예 2 내지 비교예 5에서는 단백질 발현이 아주 약간만 일어난 것을 확인 할 수 있었다. 반면, 전기적 자극만 가한 비교예 6 및 기계적 자극만 가한 비교예 7의 경우 그렇지 않은 경우보다 더 많은 단백질 발현이 관찰 되었으며, 전기적 자극과 기계적 자극을 동시에 가한 실시예 1에서는 비교예들과 비교하여 월등히 많은 심금분화 단백질 마커가 발현된 것을 관찰 할 수 있었다. As can be seen from FIG. 16, the comparison of the early differentiation factors NKX 2.5, MEF-2,
이는 도 21에 나타낸 심근분화에 관련된 분자신호에 의해 발현되는 단백질 마커들의 발현량과 비슷한 경향성을 보이는 것을 알 수 있다. It can be seen that this shows a tendency similar to that of the protein markers expressed by the molecular signal related to myocardial differentiation shown in FIG.
상기 결과에서 중간엽 줄기세포에 한가지 자극만 가해졌을 경우 보다, 전기적 자극과 기계적 자극이 동시에 가해진 경우에 심근분화가 더욱 촉진됨을 확인 할 수 있었다.
These results indicate that cardiac differentiation is further promoted when electrical stimulation and mechanical stimulation are applied at the same time as when one stimulus is applied to mesenchymal stem cells.
<시험예 4> 형광면역염색법에 의한 심근분화 유도 중간엽 줄기세포의 심근분화 관련 단백질의 발현량 Test Example 4 Induction of Myocardial Differentiation by Fluorescence Immunostaining The expression level of myocardial differentiation -related proteins in mesenchymal stem cells
상기 시험예 3에서 확인한 심근분화 관련 단백질 중 후기 분화 인자인 sarcomeric α-actinin, connexin 43을 형광면역염색법(Immunocytochemistry)으로 분석 하였다.The late differentiation factors sarcomeric alpha-actinin and connexin 43 of the myocardial differentiation-related proteins identified in Test Example 3 were analyzed by fluorescence immuno-staining (Immunocytochemistry).
세포를 4% 파라포름알데하이드(paraformaldehyde)로 상온에서 10분간 고정시킨 후 PBS로 씻어내어 준비하였다. 1차 항체로 Cx43 및 α-actinin을 사용하여 반응시킨 후, TRITC(tetramethyl rhodamine isothiocyanate) 또는 FITC(fluorescein isothiocyanate)와 결합된 2차 항체(Jackson-Immunoreseaarch, West Grove, PA, USA)를 사용하여 상온에서 1시간 동안 반응 시켰다. 모든 샘플은 DAPI(4,6-diamidino-2-phenylindole, Vector Laboratories, Burlingame, CA, USA)가 포함된 마운팅 솔루션을 이용하여 봉입(mounting)하고, 형광현미경(Olympus, Tokyo, Japan)을 사용하여 관찰 하였다.The cells were fixed with 4% paraformaldehyde at room temperature for 10 minutes and washed with PBS. The reaction was carried out using Cx43 and α-actinin as primary antibodies and then reacted with a secondary antibody (Jackson-Immunoreseaarch, West Grove, PA, USA) coupled with TRITC (tetramethyl rhodamine isothiocyanate) or FITC (fluorescein isothiocyanate) For 1 hour. All samples were mounted using a mounting solution containing DAPI (4,6-diamidino-2-phenylindole, Vector Laboratories, Burlingame, Calif., USA) and analyzed using a fluorescence microscope (Olympus, Tokyo, Japan) Respectively.
도 17a 및 17b 는 형광면역염색법에 의한 Cx43(녹색)의 발현 향상 및 sarcomeric α-actin(적색)의 발현 향상(청색 = 세포 핵, 스케일 바 = 50 μm)을 나타낸다. FIGS. 17A and 17B show the improvement of expression of Cx43 (green) and the expression of sarcomeric alpha-actin (red) by fluorescent immunoassay (blue = cell nucleus, scale bar = 50 μm).
도 17a 및 17b에 나타낸 실험 결과에서도 상기 시험예 3의 결과와 같이 전기적 자극과 기계적 자극이 동시해 가해진 실시예 1에서 월등하게 많은 심근분화 단백질 마커가 발현되는 것을 관찰 할 수 있었다.
17A and 17B, it was observed that much more myocardial differentiation protein markers were expressed in Example 1 in which electrical stimulation and mechanical stimulation were simultaneously performed, as shown in Test Example 3 above.
<시험예 5> 정량분석 역전사 중합효소 연쇄반응(qRT-PCR)≪ Test Example 5 > Quantitative analysis Reverse transcription polymerase chain reaction (qRT-PCR)
qRT-PCR 을 사용하여 이온 채널 마커인 cyclic nucleotide-gated potassium channel 2(HCN2)와 calcium channel, voltage-dependent, L type, alpha 1C subunit(CACNA1C) 의 상대적인 유전자 발현량을 정량하였다. Relative gene expression levels of cyclic nucleotide-gated potassium channel 2 (HCN2) and calcium channel, voltage-dependent, L-type and alpha 1C subunit (CACNA1C) were quantified using qRT-PCR.
샘플로부터 1 mL 트리졸 시약 (Invitrogen) 과 200 μL 클로로포름을 사용하여 토탈 RNA 를 추출하였다. 라이시스된 샘플을 12,000 rpm 의 속도로 4 ℃에서 10분간 원심분리하였다. RNA 펠렛을 75 %(v/v) 에탄올을 이용하여 씻어주고 건조시킨 후, RNase-프리 워터에 용해시켰다. qRT-PCR 을 위해 iQ™ SYBR Green Supermix kit (Bio-Rad) 와 MyiQ™ single color Real-Time PCR Detection System (Bio-Rad)을 사용하였다. β-actin을 인터널 컨트롤로 사용하였다. Total RNA was extracted from the sample using 1 mL of the trizol reagent (Invitrogen) and 200 μL of chloroform. The lysed samples were centrifuged at 4,000C for 10 minutes at a rate of 12,000 rpm. The RNA pellet was washed with 75% (v / v) ethanol, dried and dissolved in RNase-free water. For qRT-PCR, iQ ™ SYBR Green supermix kit (Bio-Rad) and MyiQ ™ single color Real-Time PCR Detection System (Bio-Rad) were used. β-actin was used as an internal control.
도 18은 qRT-PCR에 의한 HCN2 및 CACNA1C의 발현 평가 결과를 나타낸다. Fig. 18 shows the results of evaluation of expression of HCN2 and CACNA1C by qRT-PCR.
상기 결과에서도 중간엽 줄기세포에 한가지 자극만 가해졌을 경우 보다, 전기적 자극과 기계적 자극이 동시에 가해진 경우에 심근분화가 더욱 촉진됨을 확인 할 수 있다.
In the above results, it can be confirmed that the cardiac differentiation is further promoted when the electrical stimulation and the mechanical stimulation are simultaneously applied, as compared with the case where only one stimulation is applied to the mesenchymal stem cells.
<시험예 6> 중간엽 줄기세포의 심근분화 메커니즘과 관련된 인자들의 발현량 비교-역전사 중합효소 연쇄반응(RT-PCR) Test Example 6 Comparison of Expression Levels of Factors Related to Myocardial Differentiation Mechanism of Mesenchymal Stem Cells - RT-PCR (Reverse Transcription Polymerase Chain Reaction)
도 19는 전기적 자극 및 기계적 자극에 따른 hMSC의 심근분화 메커니즘의 모식도이다. 도 19에 나타낸 바와 같이, 심근분화 메커니즘에서, 전기장을 포함한 전기적 신호 혹은 기계적 자극을 가했을 경우 중간엽 줄기세포에서는 자가분비 혹은 근거리분비 단백질 (BMP-4, TGF-β, vascular endothelial growth factor (VEGF), 및 IGF)의 발현량이 늘어날 수 있다. 19 is a schematic diagram of a mechanism of myocardial differentiation of hMSC according to electrical stimulation and mechanical stimulation. As shown in FIG. 19, when electrical signals including mechanical fields or mechanical stimuli are applied to the myocardial differentiation mechanism, autocrine or near secretory proteins (BMP-4, TGF-beta, vascular endothelial growth factor , And IGF) can be increased.
구체적으로, 전기적 자극에 의하여 발현된 BMP-4에 의해서 SMAD-1,4,5,8 의 인산화 반응이 일어나고, 이러한 인산화 반응에 의해서 NKX 2.5, MEF-2 및 β-MHC의 발현량을 높여주며, VEGF와 TGF-β에 의해서 간극결합 단백질의 일종인 connexin43의 발현량이 높아진다고 알려져 있다. IGF는 p38의 인산화 반응을 증대시키고 MEF-2의 발현량을 높여줌으로써 심근분화를 야기한다. Specifically, phosphorylation of SMAD-1, 4, 5, 8 occurs by BMP-4 expressed by electrical stimulation, and the expression of NKX 2.5, MEF-2 and β-MHC is increased by this phosphorylation reaction , VEGF and TGF-β are known to increase the expression of connexin43, a type of gap junction protein. IGF increases myocardial differentiation by increasing the phosphorylation of p38 and increasing the expression of MEF-2.
전기적 자극에 의한 심근분화와 관련된 자가분비 인자인 BMP-4, TGF-β, VEGF, 및 IGF에 대하여 역전사 중합효소 연쇄반응법을 이용하여 발현을 비교하였다.Expression of BMP-4, TGF-β, VEGF, and IGF, which are related to myocardial differentiation by electrical stimulation, was compared using reverse transcription polymerase chain reaction.
샘플을 트리졸 시약(TRIzol reagent, Invitrogen Carlsbad, CA, USA)처리하여 라이시스시키고, 토탈 RNA는 클로로폼(chloroform, Sigma)으로 추출하고, 80 %(v/v) 이소프로판올(isopropanol, Sigma)로 침전시킨 후, 상층액을 제거하고 침전된 RNA 펠렛을 75 %(v/v) 에탄올을 이용하여 씻어주고 건조시킨 후, 0.1 %(v/v) DEPC 처리된 물(diethyl pyrocarbonate-treated water)로 펠렛을 녹여 순수한 토탈 RNA를 얻었다.Samples were lysed by treatment with TRIzol reagent (Invitrogen Carlsbad, CA, USA) and the total RNA was extracted with chloroform (Sigma) and eluted with 80% (v / v) isopropanol After precipitation, the supernatant was removed, and the precipitated RNA pellet was washed with 75% (v / v) ethanol and dried, and then washed with 0.1% (v / v) DEPC treated diethyl pyrocarbonate- The pure total RNA was obtained by dissolving the pellet.
상기의 방법으로 추출한 토탈 RNA를 SuperScriptTM II reverse transcriptase (Invitrogen)을 이용하여 cDNA 합성하였다.The total RNA extracted with the method of the cDNA was synthesized using SuperScript TM II reverse transcriptase (Invitrogen) .
합성한 cDNA는 94℃에서 30초간 열변성(denaturing), 58℃에서 45초간 풀림(annealing), 72℃에서 45초간 신축(extending)의 사이클을 35회 반복하고, 마지막으로 72℃에서 10분간 최종 신축(final extension)의 PCR 증폭 조건으로 증폭하고, 2%(w/v) 아가로즈 겔에 전기영동하고 Et-Br(ethidium bromide)염색한 후, 겔 도큐멘테이션 시스템(Gel Doc 100, Bio-Rad, Hercules, CA, USA)를 이용하여 분석하고, 이미징 농도계(Imaging densitometer, Bio-Rad)를 이용하여 정량 하였다. 또한, 상기 시험에 있어서 β-actin을 인터널 컨트롤로 사용하였다.The synthesized cDNA was subjected to denaturation at 94 ° C for 30 seconds, annealing at 58 ° C for 45 seconds and extension at 72 ° C for 45 seconds, followed by 35 cycles of incubation at 72 ° C for 10 minutes (Gel
도 20은 RT-PCR 방법에 의한 BMP-4, IGF, VEGF 및 TGF-β의 발현 평가 결과이다. 도 20에 나타낸 실험결과에서 심근분화와 관련된 자가 분비 인자인 BMP-4, IFG, VEGF 및 TGF-β의 발현량이 실시예 1의 경우 월등히 높은 것을 관찰 할 수 있었다. 20 shows the results of evaluation of expression of BMP-4, IGF, VEGF and TGF-? By the RT-PCR method. 20, the expression levels of BMP-4, IFG, VEGF and TGF-beta, which are self-secretion factors related to myocardial differentiation, were remarkably high in Example 1.
도 21은 시험예 3에서 설명한 웨스턴 블롯 방법에 의한 p38, SMAD, FAK, ERK1/2의 발현을 나타낸다. 중간엽 줄기세포는 자가 분비 인자에 의해 자극되기 때문에 도 21에서 보는 바와 같이, 전기적 및 기계적 자극은 심근분화용 세포간 시그널링 분자(pp38 및 pSMAD)의 단백질 발현을 더욱 증대시켰음을 알 수 있다. 또한, focal adhesion kinase (FAK) 및 extracellular signal-regulated kinases 1/2 (ERK1/2)의 인산화가 기계적/전기적 자극에 의해 강화되었다. ERK1/2의 인산화는 GATA4 발현을 강화시킴으로써 심근분화를 야기한다. 전기적 및 기계적 신호 중 어느 하나만 가해졌을 때 보다 동시에 가해졌을 때 p38, SMAD, FAK, ERK1/2 와 비교하여 pp38, pSMAD, pFAK, pERK1/2가 더욱 강화되었다.
FIG. 21 shows the expression of p38, SMAD, FAK and ERK1 / 2 by the Western blotting method described in Test Example 3. As shown in FIG. 21, since the mesenchymal stem cells are stimulated by the autocrine factors, it can be seen that the electrical and mechanical stimulation further enhanced the protein expression of intercellular signaling molecules (pp38 and pSMAD) for myocardial differentiation. In addition, phosphorylation of focal adhesion kinase (FAK) and extracellular signal-regulated
이상과 같은 결과로부터 중간엽 줄기세포에 한가지 자극만 가해졌을 경우 보다, 전기적 자극과 기계적 자극이 동시에 가해진 경우에 심근분화가 더욱 촉진됨을 확인 할 수 있었다. These results suggest that cardiomyocyte differentiation is promoted when electrical stimulation and mechanical stimulation are applied at the same time as when one stimulus is applied to mesenchymal stem cells.
Claims (16)
상기 줄기세포가 접종된 지지체에 운동력을 가하여 줄기세포를 심근세포로 분화시키는 단계를 포함하는 줄기세포의 분화 방법.Inoculating stem cells onto a support having both piezoelectricity and elasticity, and
And dividing the stem cells into myocardial cells by applying a mobility to the support on which the stem cells have been inoculated.
상기 운동력은 굴신(屈伸) 운동 및 신축(伸縮) 운동 중 어느 하나이거나 두 가지가 동시에 가해지는 것인, 줄기세포의 분화 방법.The method according to claim 1,
Wherein the exercise force is either one of a bending and stretching motion and a stretching motion, or both.
상기 지지체에 가해지는 굴신 운동 또는 신축 운동은 지지체의 압전성을 이용하여 전기적 에너지 및 기계적 에너지를 발생시키는 것인, 줄기세포의 분화 방법. 3. The method of claim 2,
Wherein the stretching or stretching motion applied to the support generates electrical energy and mechanical energy using the piezoelectricity of the support.
상기 전기적 에너지는 상기 지지체를 0.1 ~ 10 Hz 빈도로 굽혔다 펴주는 운동에 의해 0.1 ~ 10 V의 전압을 발생시키는 것인, 줄기세포의 분화 방법. The method of claim 3,
Wherein the electrical energy generates a voltage of 0.1 to 10 V by bending and rolling the support at a frequency of 0.1 to 10 Hz.
상기 기계적 자극은 상기 지지체를 0.1 ~ 10 Hz 빈도로 원래 길이 대비 1 ~ 20%의 길이를 늘렸다가 수축시키는 운동에 의해 발생시키는 것인, 줄기세포의 분화 방법.The method of claim 3,
Wherein the mechanical stimulation is generated by a movement of increasing the length of the support by 1 to 20% relative to the original length at a frequency of 0.1 to 10 Hz and contracting the support.
상기 줄기세포는 지지체에 가해지는 운동력의 방향과 수직한 방향으로 배열되는 것인, 줄기세포의 분화 방법.The method according to claim 1,
Wherein the stem cells are arranged in a direction perpendicular to the direction of the kinetic force applied to the support.
상기 줄기세포는 지방 줄기세포, 중간엽 줄기세포, 골수 줄기세포, 제대혈 줄기세포, 신경줄기세포 및 유도만능 줄기세포로 구성된 군으로부터 선택되는 것인, 줄기세포의 분화 방법.The method according to claim 1,
Wherein the stem cells are selected from the group consisting of adipose stem cells, mesenchymal stem cells, bone marrow stem cells, cord blood stem cells, neural stem cells and induced pluripotent stem cells.
상기 지지체는 탄성층과 압전물질층이 1회 이상 교대로 적층된 구조를 가지되, 탄성층이 최외곽층을 형성하는 것인, 줄기세포의 분화 방법.The method according to claim 1,
Wherein the supporter has a structure in which an elastic layer and a piezoelectric material layer are alternately laminated one or more times, and the elastic layer forms an outermost layer.
상기 압전물질층은 복수의 압전물질 나노로드를 포함하는 것인, 줄기세포의 분화 방법. 9. The method of claim 8,
Wherein the piezoelectric material layer comprises a plurality of piezoelectric substance nanorods.
상기 압전물질 나노로드는 이축 성장 압전물질 나노로드인 것인, 줄기세포의 분화 방법.10. The method of claim 9,
Wherein the piezoelectric material nanorod is a biaxial growth piezoelectric material nanorod.
상기 압전물질 나노로드는 사이에서 일방향으로 배열되어 압전물질층을 형성하는 것인, 줄기세포의 분화 방법.10. The method of claim 9,
Wherein the piezoelectric material nanorods are arranged in one direction between the piezoelectric material nanorods to form a piezoelectric material layer.
상기 압전물질 나노로드는 일방향 단일층으로 배열된 것인, 줄기세포의 분화 방법.10. The method of claim 9,
Wherein the piezoelectric material nanorods are arranged in a unidirectional monolayer.
상기 탄성층은 외부로부터 인가되는 기계적 에너지를 상기 압전물질층에 전달할 수 있는 재료로 이루어진 것인, 줄기세포의 분화 방법. 9. The method of claim 8,
Wherein the elastic layer is made of a material capable of transmitting mechanical energy applied from the outside to the piezoelectric material layer.
상기 탄성층은 상기 압전물질층으로부터 발생되는 압전 전위를 접종된 줄기세포에 전달할 수 있는 재료로 이루어진 것인, 줄기세포의 분화 방법.9. The method of claim 8,
Wherein the elastic layer is made of a material capable of transferring the piezoelectric potential generated from the piezoelectric material layer to the inoculated stem cells.
상기 탄성층은 유전상수를 갖는 유전물질을 포함하는 재료로 이루어진 것인, 줄기세포의 분화 방법.9. The method of claim 8,
Wherein the elastic layer is made of a material including a dielectric material having a dielectric constant.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150078511A KR20160142587A (en) | 2015-06-03 | 2015-06-03 | Method for cardiomyogenic differntiation of stem cells by applying electric and mechanical signals |
| PCT/KR2016/004341 WO2016195247A2 (en) | 2015-06-03 | 2016-04-27 | Method for differentiating stem cells into cardiomyocytes by applying electric and mechanical stimuli |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150078511A KR20160142587A (en) | 2015-06-03 | 2015-06-03 | Method for cardiomyogenic differntiation of stem cells by applying electric and mechanical signals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160142587A true KR20160142587A (en) | 2016-12-13 |
Family
ID=57440640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150078511A Ceased KR20160142587A (en) | 2015-06-03 | 2015-06-03 | Method for cardiomyogenic differntiation of stem cells by applying electric and mechanical signals |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR20160142587A (en) |
| WO (1) | WO2016195247A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210064081A (en) * | 2019-11-25 | 2021-06-02 | 한국생산기술연구원 | Cell culture device and method for cell culture using the same |
| KR102283340B1 (en) * | 2020-03-27 | 2021-07-30 | 서울대학교산학협력단 | Cardiac-mimetic cell culture platform and a method for direct cardiac reprogramming |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3351291B1 (en) * | 2017-01-20 | 2022-11-23 | Consejo Superior de Investigaciones Científicas (CSIC) | Self-generating voltage device for electrical cell stimulation, and method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2392315C2 (en) * | 2003-10-03 | 2010-06-20 | Кейити ФУКУДА | Method of stem cells differentiation into miocardial cells induction |
| IT1394977B1 (en) * | 2009-04-14 | 2012-08-07 | Fond Istituto Italiano Di Tecnologia | ELECTRIC CELL STIMULATION MEDIATED BY PIEZOELECTRIC NANOTUBES |
| KR101344719B1 (en) * | 2011-07-19 | 2013-12-26 | 한국과학기술연구원 | The method for differentiating stem cells into smooth muscle cells with strain and tissue engineering complex containing the smooth muscle cells |
| KR101497338B1 (en) * | 2013-12-31 | 2015-03-25 | 연세대학교 산학협력단 | Medical patch |
| CN104388311B (en) * | 2014-11-20 | 2016-09-21 | 杭州电子科技大学 | Organizational project stem cell inducing cardiomyocytes is cultivated and measures bioreactor |
-
2015
- 2015-06-03 KR KR1020150078511A patent/KR20160142587A/en not_active Ceased
-
2016
- 2016-04-27 WO PCT/KR2016/004341 patent/WO2016195247A2/en not_active Ceased
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210064081A (en) * | 2019-11-25 | 2021-06-02 | 한국생산기술연구원 | Cell culture device and method for cell culture using the same |
| KR102283340B1 (en) * | 2020-03-27 | 2021-07-30 | 서울대학교산학협력단 | Cardiac-mimetic cell culture platform and a method for direct cardiac reprogramming |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016195247A3 (en) | 2017-01-26 |
| WO2016195247A2 (en) | 2016-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Electroactive biomaterials and systems for cell fate determination and tissue regeneration: design and applications | |
| Ji et al. | Research trends of piezoelectric nanomaterials in biomedical engineering | |
| Yoon et al. | Stretchable piezoelectric substrate providing pulsatile mechanoelectric cues for cardiomyogenic differentiation of mesenchymal stem cells | |
| Ricotti et al. | Adhesion and proliferation of skeletal muscle cells on single layer poly (lactic acid) ultra-thin films | |
| US12427227B2 (en) | Bioactive smart scaffolds for regenerative medicine | |
| Yow et al. | A 3D electroactive polypyrrole-collagen fibrous scaffold for tissue engineering | |
| Baryshyan et al. | Self-assembled insect muscle bioactuators with long term function under a range of environmental conditions | |
| KR20160142587A (en) | Method for cardiomyogenic differntiation of stem cells by applying electric and mechanical signals | |
| KR102477753B1 (en) | Implantable electrode | |
| Liu et al. | In vitro cardiomyocyte-driven biogenerator based on aligned piezoelectric nanofibers | |
| KR20140098273A (en) | Preparation method of implant comprising drug delivery layer and implant compostion for living donor transplantation comprising the same | |
| CN106701824A (en) | Method for obtaining spinal motoneurons and functional cells thereof based on human iPS (induced pluripotent stem) cells | |
| Panda et al. | Tunable substrate functionalities direct stem cell fate toward electrophysiologically distinguishable neuron-like and glial-like cells | |
| US10245426B2 (en) | Medical patch | |
| CN106047802B (en) | A material for promoting osteogenic differentiation of mesenchymal stem cells, preparation method and application thereof | |
| Kumari et al. | Conductive polyisocyanide hydrogels inhibit fibrosis and promote myogenesis | |
| CN111254108B (en) | Silk protein hydrogel and its preparation method and application | |
| CN110819588B (en) | Application of Piezoelectric Materials in Stem Cell Proliferation and/or Differentiation | |
| Lv et al. | Self-adhesive ultrasound-mediated triboelectric nanogenerator device for subcutaneous antibacterial treatment and accelerated wound healing | |
| CN102533640A (en) | Method for generating adult stem cells into spheroid cell populations | |
| Webster et al. | Fabrication of electrocompacted aligned collagen morphs for cardiomyocyte powered living machines | |
| ES2708220T3 (en) | Implantable device with selective cell adhesion and production method | |
| CN113456894B (en) | Preparation method of polypyrrole/gelatin fiber scaffold and product thereof | |
| Cheng et al. | Electrochemical bioencapsulation of nanomaterials into collagen for biomedical applications | |
| Li et al. | Organ synergy in poly (vinylidene fluoride)-based piezoelectrical materials for tissue engineering |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20150603 |
|
| PA0201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20161116 Patent event code: PE09021S01D |
|
| PG1501 | Laying open of application | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20170227 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20161116 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |